As it races to create a vaccine for the novel coronavirus, the Trump administration this month announced that one of its largest pandemic-related contracts would go to a little-known biodefense company named Emergent BioSolutions. “Emergent’s manufacturing capabilities will pave the way,” Health and Human Services Secretary Alex Azar said in a statement.
The $628 million deal to help manufacture an eventual vaccine cemented Emergent’s status as the highest-paid and most important contractor to the HHS office responsible for preparing for public health threats and maintaining the government’s stockpile of emergency medical supplies.
Emergent has long been the government’s sole provider of BioThrax, a vaccine for anthrax poisoning. But over the past decade, the company has acquired biodefense competitors and treatments for smallpox, botulism and other threats for which there is no market outside of government. Continue reading.